Aerospace 27% growth, margins firm amid cost headwinds
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade A
Q1 guidance (25% aerospace, aftermarket Q2, Andhra late '27) all delivered or on track; capex plan reaffirmed.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q2 execution (24% revenue, 131% PAT on surgical precision growth + cost control) but guidance is measured ('high mid-20s' aerospace, no company-wide FY27 target). Management trading on prior 40% Q1 aerospace growth for caution—sustainable strategy, but near-term upside capped. Andhra facility (₹400 Cr spend, Dec 2027) is a 3-year bet; margin expansion (25% aerospace target) hinges on cost normalization.
₹655.2 Cr
Revenue · +24.2% YoY₹32.1 Cr
Reported PAT · +130.8% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 total income 21% YoY; aerospace 27% YoY growth
METRevenue 655.2 Cr (24.2% YoY); aerospace 139 Cr (27% match)
EBITDA margin 15.1%; precision margin 13%
METOPM 11.5%; NPM 4.7% (EBITDA 103 Cr ÷ 683 income ≈ 15.1% stated)
Aftermarket operationalized Q2 FY27
METConfirmed: officially operationalized during quarter
Earnings quality
What changed since the last call
Aerospace growth hedged
NeutralQ1 FY27 delivered 40% aerospace growth; Q1 call reiterated 25% guidance. Q2 delivered 27% but management now commits only to 'high mid-20s', discouraging 40% repeat expectations.
Andhra capex reaffirmed
Neutral₹1,000 Cr over 5 years unchanged; ₹400 Cr to be spent by facility start (Dec 2027). No upward revision despite inflation; suggests cost discipline.
Margin targets stable
NeutralPrecision auto 12–13% maintained; aerospace 25% mature level unchanged. No margin expansion guidance this quarter, implying cost pressures are real and near-term expansion limited.
The Q&A
Analysts pressed on order book quantum, Andhra ROI payback period, and cost-pass-through feasibility. Management deflected order book specifics (citing scheduling volatility), acknowledged freight/raw material hedging via customer contracts, and stressed operating leverage as offset. Defense order details withheld. Tone: defensive but measured—analysts had teeth but lacked specific targets to pin mgmt down.
Aerospace capacity expansion — Dheeraj, InCred Equity
AnsweredMachines already added; now targeting INR700–750 Cr from INR600–650 Cr current. More machinery procurement ongoing; ultimate goal INR750 Cr but timeline flexible based on demand.
Automotive aftermarket — Sahil Karia, White Pine Investment Management
PartialEntered August; ~800 part numbers, strong traction; margins better than OE. Not providing numbers yet but position attractive due to white-label supply chain leverage.
Aerospace growth rate — Balasubramanian, Arihant Capital
AnsweredQ2 was good year; growth will moderate to 'high mid-20s', not 40%. This year has been strong but growth will be muted into FY28 due to base comparisons and ramp-up gating.
Aerostructure margins — Keval Shah, Sanctum Wealth PMS
PartialTarget long-term ROCEs between 20–25%; margins depend on scale and vertical integration at Andhra. Approvals to be compressed via existing platform leverage; strategic move balances near-term headwinds with long-life cycle visibility.
Order book & backlog — Chirag Jain, Spark Capital
DodgedOrders are large and growing daily; order positions fluctuate due to platform ramps and delivery schedules. OEMs have backlogs >12 years; we're on platform, market share rising. Cannot quantify precisely due to scheduling volatility.
LEAP engine revenue content — Sagar Shetty, Wealthyvia
PartialInitial shipment value ~$35,000; will grow as market share and content expand. Difficult to project due to market dynamics; focus on execution, not numbers.
Precision tech segment growth — Navin Sharma (CFO answering)
AnsweredB2B ~INR350 Cr, B2C ~INR120 Cr (Precision Technology segment). B2B roughly 17–18% growth, B2C in early teens. Tools/hardware (JKF) also growing.
Andhra facility PPAP timeline — Vignesh Iyer, Sequent Investments
AnsweredCommercial production starts Dec 2027 (Q3 FY28). PPAP approvals typically 3–9 months post-plant validation; customer approvals ongoing in parallel with infrastructure; no deferral.
Cost inflation & pricing — Balasubramanian (follow-up)
AnsweredRaw material is pass-through; freight negotiated per contract—some we absorb, some customers share. Operating leverage from volume is offsetting cost pressures; margins stable despite freight/commodity headwinds.
Medical & adjacency opportunities — Keval Shah (follow-up)
PartialCurrently in sample/pilot phase; approvals 6 months away. Nascent but strategic; targeting adjacency ROCE evaluation based on quality/margins. Not declaring numbers; exploring optionality.
Guidance
Aerospace 'high mid-20s' YoY growth (FY27 onwards); no company-wide FY27 revenue target stated
HighManagement committed to this range after delivering 27% in Q2; implies FY27 YoY growth likely 24–28%. Backward-looking—no forward FY28 target given.
Aerospace target 25% EBITDA margin (mature level); precision auto 12–13%
MediumAerospace at 21% Q2, 110 bps short of target; precision holding 13%. Margin expansion contingent on cost normalization (freight, raw materials) and Andhra scale benefits—neither assured in FY27.
₹1,000 Cr capex over 5 years (₹510 Cr aerospace, ₹430 Cr auto); Andhra greenfield ₹400 Cr spend by Dec 2027 start
HighReaffirmed without revision; modular facility design allows phased capex; no indication of inflation-driven scope creep or timeline slip.
Risks the call surfaced
Commodity & freight cost
HighPersistent freight, raw material (tool steel, nickel), and logistics costs compress operating margins; pass-through to customers incomplete and contractually lagged.
Order book concentration
MediumAerospace revenue concentrated on LEAP engine and 2–3 OEM platforms (Boeing, Airbus). Market share 35–65% varies by part; order visibility opaque—backlog stated as 'large' but no quantum given.
Andhra capex execution
Medium₹400 Cr Andhra greenfield facility must open Dec 2027 for on-time delivery roadmap. Delays in PPAP approvals, customer validations, or construction/equipment procurement could push commercial production into Q4 FY28 or beyond, delaying margin accretion.
Automotive aftermarket execution
LowAftermarket launched Q2 FY27 with 800 part numbers; market is fragmented and price-competitive; scaling customer base, distribution, and margin profile uncertain.
Geopolitical supply-chain risk
MediumAerospace exports face U.S. ITAR compliance and tariff risk; Middle East shipping disruptions mentioned; Chinese auto OEM competition in Europe could displace Raymond components.
Management
Score 7/10. Clear on segment performance and strategy (Andhra facility, aftermarket, platform expansion). Hedges on order book specifics and near-term guidance—defensive but transparent about constraints (freight costs, approval timelines). Does not overcommit. Track record strong: Q1 guidance delivered (40% aerospace growth exceeded 25% target; aftermarket on schedule; capex plan maintained). Missing: no company-wide FY27 revenue target stated; management pulling back on growth rate expectations ('high mid-20s' vs prior 40% Q1) shows prudence or caution.
1 · Q3 FY27 (Dec 2026)
Andhra greenfield commercial production ramps; pricing power tests with larger OEM packages
2 · Q4 FY27 (Mar 2027)
Boeing/Airbus ramp-up intensifies post-destocking; LEAP engine volume acceleration expected
3 · FY28 (Apr–Dec 2027)
Andhra facility contributes material revenue (target ₹700–750 Cr from current ₹600–650 Cr); defense contract (unnamed) begins delivery
Andhra facility (₹400 Cr spend, Dec 2027) is a 3-year bet; margin expansion (25% aerospace target) hinges on cost normalization.
Aerospace Momentum & Margin Expansion: The Transition Quarter
Raymond's pivot from textiles to defence & engineering is accelerating. Q2 will test whether Q1's aerospace beat (+40% vs guidance) and 50% profit growth can sustain amid capex deployment and a fouling FII ownership base.
The Setup: Racing Ahead on Aerospace
Raymond is no longer primarily a textiles company. Q1 FY27 delivered ₹605.61 Cr revenue and ₹30.85 Cr PAT (adjusted +50% YoY), with aerospace surging 40% above internal guidance. The Board has approved a name change to Raymond Aerospace, Defence & Engineering Limited, signalling a wholesale strategic rebranding. For Q2, the Street will be watching whether this momentum holds and whether margin expansion continues as the business scales its capex footprint.
~₹620–640 Cr
building on Q1's ₹605.61 Cr run-rate + aerospace contribution ramp
~₹35–40 Cr
on guided margin trajectory from Q1's ₹30.85 Cr; test: can capex burn be absorbed?
growing high-teens %
Q1 was >₹90 Cr run-rate; new orders + production ramp underway
₹100 Cr p.a. committed
Andhra Pradesh brownfield facility + equipment for aerospace doubling plan over 4–5 years
On Track? Guidance vs Reality
Raymond's stated plan: double aerospace revenue over 4–5 years; target EBITDA margins of 22–25% for the aerospace division (vs ~18–19% in Q1). The company secured ₹33 Cr of annual orders in September and entered the aircraft structures vertical in the same window—a high-stakes move in a capex-intensive, long-lead-time market. Q1 beat its own guidance by 40% on aerospace, suggesting internal estimates are conservative. The risk: ₹100 Cr annual capex is real cash outflow. Expect Q2's cash flow and balance-sheet commentary to be under the microscope; any slowdown in order inflow or slippage in ramp timelines would be a material miss vs Street expectations.
What the Street Expects
Since Last Quarter: The Event Scan
October has been a flurry of corporate action. Board approved name change to Raymond Aerospace, Defence & Engineering Ltd (subject to shareholder approval). Preferential issue of ₹214.71 Cr closed (33.3 Lakh warrants to Minerva Ventures Fund @ ₹645/warrant, convertible @ ₹497)—capex ammunition is in place. Andhra Pradesh expansion accelerating with a new brownfield facility to meet demand. Aircraft structures win (wing and center fuselage assembly for a major Indian aerospace OEM) is strategic validation of the pivot.
Ownership: FII stake has halved YoY from 15.6% to 7.9%—a 786 bps decline in nine months. DII flat. Promoter steady at 48.87%. Bulk/block dealing in late September saw rotations between HRTI Private Limited and QE Securities (both appear to be fund/nominee entities), no sign of promoter distress but the FII withdrawal is notable amid a down-20% move from ATH.
A Strong Print vs A Weak One
Strong print: Revenue ₹630+ Cr, PAT ₹38+ Cr (margins 6%+ adjusted), aerospace >₹100 Cr with EBITDA expanding toward 20%, and management guidance reiterating the 4–5 year double with no order-inflow slowdown. Weak print: Revenue flat or down QoQ, PAT <₹32 Cr (margin compression below 5%), aerospace stalling below ₹100 Cr, or capex burn revealing cash-flow stress. Watch for: order book depth, production ramp visibility, gross margin (textile vs aerospace mix matters), and working-capital impact of the Andhra Pradesh ramp.
1 · Aerospace order inflow & production cadence
Did the ₹33 Cr annual run-rate translate into Q2 revenue? Are the aircraft structures and machining wins actually producing revenue, or are they future backlog? Look for order-book guidance and timeline for ramp.
2 · Margin bridge: textile vs aerospace mix
If aerospace (higher-margin) grew faster than textile (lower-margin), will reported EBITDA % expand? If textile softened, could aerospace growth be masked by mix deterioration? Segment margins are key.
3 · CapEx cash outflow and FCF impact
₹100 Cr annual capex is now live. Did Q2 capex deployment appear on cash flow statement? Any impact on net debt? Investors will stress-test the capex plan against free cash flow generation.
4 · FII ownership & shareholder base churn
Why are FIIs exiting (down 786 bps YoY)? Is it valuation (stock down 20% from ATH) or conviction loss on execution? Management commentary on capital allocation and shareholder return will matter.
Raymond Q2: consolidated PAT up sharply YoY, aerospace surges 72%; auto margin lags
PAT +130.81% YoY · revenue +24.16% · margins expanding
₹655.16 Cr
+24.16% YoY
₹32.06 Cr
+130.81% YoY
4.69%
+2.2pp YoY
₹3.36
Raymond's consolidated PAT for Q2 FY27 (quarter ended September 30, 2026) came in at ₹32.06 Cr, up 130.8% year-on-year from ₹13.89 Cr and 3.9% sequentially from ₹30.85 Cr, on consolidated revenue of ₹655.16 Cr (+24.2% YoY, +8.2% QoQ). The year-ago quarter's PAT, however, sat on top of a ₹167.40 Cr exceptional 'reversal of goodwill' charge tied to an NCLT-approved scheme that was almost entirely offset by a linked ₹175.86 Cr deferred-tax credit — stripping both sides out, adjusted PAT a year ago was closer to ₹14.3 Cr, putting adjusted YoY PAT growth at roughly +124%, still very strong and close to the reported number since the one-off was largely self-cancelling at the PAT line this time rather than inflating it.
Q2 FY-2027 vs prior quarters
The growth is almost entirely an aerospace & defence story: segment revenue rose 71.9% YoY to ₹139.36 Cr — far ahead of management's reiterated 25% full-year target and even Q1's already-elevated 40% pace — lifting aerospace to 21.3% of segment revenue from 15.4% a year ago. Aerospace segment margin expanded to 13.3% from 8.9% YoY and 12.7% in Q1, moving toward, though still well short of, management's stated 25% 'mature' margin level. Precision technology & auto, the larger segment at ₹470.61 Cr revenue (+15.0% YoY), told the opposite margin story: segment margin fell to 8.57% from 9.40% in Q1 and was roughly flat YoY (9.04%), missing management's own 12-13% target band. At the consolidated level this nets out to an operating margin of 11.50%, down from 12.76% in Q1 (sequential compression) though well above the ~8.2% underlying year-ago level once the exceptional item is excluded; net margin eased to 4.69% from 4.91% QoQ.
The stock went into the print at ₹1,088.7, down 9.6% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
Reiterate 25% YoY Aerospace growth (outperformed Q1 at 40%). Target Aerospace margins 25% mature level; Precision auto 12-13%. ₹1,000 Cr 5-year capex (₹510 Cr aerospace, ₹430 Cr auto); Andhra Pradesh greenfield commercial production late 2027. Aftermarket rollout Q2 FY27.
— This quarter: beat
No specific Street consensus for this quarter could be confirmed via search, so vsStreet is marked unknown rather than guessed. Against the company's own prior guidance — 25% YoY aerospace growth, a 25% mature aerospace margin and a 12-13% precision-auto margin, all reiterated on the Q1 FY27 call — the quarter is a clear beat on the aerospace growth line but a miss on the auto margin line. The print lands alongside several structural moves: the board's October 24 decision to rename the company 'Raymond Aerospace, Defence & Engineering Ltd', formalizing the pivot; a ₹82.72 Cr upfront warrant subscription from promoter entity JK Investors during the quarter (25% of a ₹497/warrant, 66.57 lakh-warrant issue) with a further ₹214.70 Cr warrant issue to Minerva Ventures Fund approved just after quarter-end; and continued Andhra Pradesh greenfield expansion work, all funding the ₹1,000 Cr five-year capex plan (₹510 Cr aerospace, ₹430 Cr auto) targeting commercial production there in late 2027. No management press release text was available for this filing, so this framing is drawn from the reported numbers and filing notes rather than management's own commentary.
W1
Precision auto segment margin recovery toward the 12-13% target band (currently 8.57%, down from 9.40% in Q1)
W2
Aerospace segment margin progression toward the stated 25% 'mature' level (currently 13.3%, up from 12.7% in Q1)
W3
Andhra Pradesh greenfield facility progress toward late-2027 commercial production and deployment of the ₹1,000 Cr capex plan funded partly via the warrant issues
Clear, legible scans throughout; both statements' column headers (30.09.2026 vs 30.06.2026 vs 30.09.2025) unambiguous. Consolidated is primary — standalone Raymond Ltd is now largely a holding entity (operating business sits in subsidiaries post the realty demerger and MPPL scheme), so standalone revenue (₹0.56 Cr) is not comparable to consolidated. Year-ago quarter (30.09.2025) carried a ₹167.40 Cr exceptional 'reversal of goodwill' loss (NCLT scheme, note 3) that was almost fully offset by a linked ₹175.86 Cr deferred-tax credit tied to the same DTL reversal — flagged for adjusted YoY PAT treatment. No minority interest adjustment needed for PAT (DB convention uses total profit for the period including NCI, confirmed against prior-quarter context figures).
Raymond's Aerospace Engine Runs Strong—But Operating Margins Don't (Yet)
The quarter delivered 24% revenue growth and 27% aerospace expansion, but operating margin has stalled at 11.5% amid freight and commodity headwinds. Management hedged guidance on margin recovery timing. The question: can Andhra facility and cost normalization unlock margin upside, or is this a structural squeeze?
₹655.2 Cr
+24.2% YoY
₹32.1 Cr
+130.8% YoY (base-dependent)
11.5%
flat YoY (freight headwind)
27% YoY
₹139 Cr, margin 21%
The quarter delivered everything on the revenue side: 24% growth, aerospace outperforming guidance at 27%, and the Andhra capex project tracking to plan. But there's a gap between the headline growth and what's happening at the profit line. Operating margin has stalled at 11.5%, caught in a vise of freight and raw-material cost inflation that management has not yet cracked. The real story is whether that margin can recover, or whether the company is trapped in a structural squeeze.
The PAT beat is real, but the base is low
Reported PAT of ₹32.1 Cr jumped 130.8% YoY—a headline that catches the eye. But the prior-year base was depressed, making the comparison less informative. The better lens is operating performance: EBITDA margin held at 15.1%, a healthy level, but operating margin contracted to 11.5%, down from historical 13–14% levels. The gap between EBITDA (15.1%) and OPM (11.5%) is the cost of running the Andhra capex program and absorbing freight volatility. Management cited that "key commodity and raw material prices... remained firm at elevated levels, alongside persistent freight and logistics volatility." The company did not commit to a timeline for margin recovery, a notable absence given the revenue strength.
Key commodity and raw material prices, including tool costs, have remained firm at elevated levels, alongside persistent freight and logistics volatility.
Aerospace 27% YoY growth; precision 15% YoY
Aerospace ₹139 Cr (+27% YoY); precision ₹471 Cr (+15% YoY)
Supported
EBITDA margin 15.1%; precision segment 13%
EBITDA 103 Cr ÷ 683 Cr total income ≈ 15.1%; precision margin 13%
Supported
Aerospace margin target 25% (mature level)
Q2 delivered 21% (110 bps short); contingent on cost normalization + Andhra scale, no commitment timeline
Hedged—target intact, timeline unclear
High mid-20s aerospace growth guidance (reiterated)
Delivered 27% Q2; management pulled back from 'reiterate 25%' (Q1) to 'high mid-20s' now
Supported but cautious
Andhra greenfield on track for Dec 2027 commercial production
PPAP approvals in parallel with site infrastructure; ₹400 Cr spend by start on schedule
Supported—execution risk remains (PPAP delays)
Aftermarket operationalized Q2 FY27 (per prior guidance)
Confirmed; launched with ~800 part numbers, margin profile 'better than OE'
Supported
What shifted on this call
Three things worth watching: (1) Guidance hedge on aerospace growth: Q1 call reiterated 25% YoY; Q2 call now commits only to 'high mid-20s'—a pullback after delivering 40% Q1 and 27% Q2. Management is managing expectations downward, a prudent but cautious move. (2) Capex plan unchanged: ₹1,000 Cr over 5 years (₹400 Cr aerospace, ₹430 Cr auto) reaffirmed without revision despite inflation. This signals cost discipline or a constrained investment appetite. (3) Margin targets stable but no expansion committed: Aerospace target remains 25% (vs. current 21%), precision 12–13% (at target). No new margin expansion guidance suggests management sees the near-term cost squeeze as real and isn't betting on a quick resolution.
Aerospace 27% growth outperforms guidance; LEAP market share rising
Andhra capex reaffirmed without revision—cost discipline evident
Operating margin stalled at 11.5% despite 24% revenue growth—structural squeeze
Margin expansion targets hedged; no near-term commitment to 25% aerospace margin
Order book opaque (management declined to quantify months/years of backlog)
FII ownership down 1.86pp QoQ; stock down 12.44% from ATH—institutional caution
Management credibility high (Q1 guidance delivered; track record A-grade)
Aftermarket operationalized; new growth leg with margin profile better than OE
Margin compression from freight/commodity inflation unresolved
HighOPM 11.5% vs. historical 13–14% is a 150–250 bps headwind. Pass-through to customers incomplete and contractually lagged. If costs remain sticky through FY27, margin recovery could slip into FY28, capping EPS growth.
Andhra facility execution risk (PPAP approvals, customer sign-offs, construction delays)
MediumDec 2027 commercial production start is a hard gate for FY28 margin accretion and capacity targets. Any slip into Q4 FY28 delays revenue/margin benefit by 1–2 quarters and raises capex-to-return questions.
Order book concentration and opacity
MediumAerospace revenue concentrated on LEAP engines and 2–3 OEM platforms (Boeing, Airbus). Management refused to quantify backlog (months/years of coverage). Without specific visibility, 'high mid-20s' growth guidance is harder to validate.
Automotive aftermarket scaling unproven
LowNewly launched (Q2 FY27) with ~800 part numbers. Market fragmented and price-competitive. Smaller contributor relative to aerospace and precision tech; execution risk exists but not material near-term.
How the street is positioned
The post-result price action tells a mixed story. Day 1 saw a -1.95% selloff from the ₹1,081.2 announcement close—a disappointment, likely on muted guidance and no margin expansion commentary. By day 3 the stock had recovered to +1.76%, and by day 5 it had rallied to +8.43%, as the market re-rated the quality of the underlying revenue growth (24% organic, 27% aerospace). But institutional conviction remains tentative: FII ownership fell 186 bps QoQ (from 9.75% to 7.89%), a net sell into the rally. This suggests sophisticated capital is not confident the near-term margin squeeze will ease. The stock sits at ₹1,172.3, above key moving averages (SMA20 ₹1,134.95, SMA50 ₹998.63, SMA200 ₹614.07) but remains 12.44% below its all-time high of ₹1,338.9. The drawdown reflects the market's skepticism: the growth story is intact, but near-term margin recovery and Andhra execution are not assured.
1 · Operating margin recovery signals (Q3 onwards)
The core question: do freight/commodity costs begin to normalize or do customer price increases stick? Target to watch: OPM back to 13–14% by H2 FY27 (from current 11.5%). If margin remains stuck or worsens, the aerospace growth story loses leverage.
2 · Andhra facility PPAP approvals and Dec 2027 start confirmation (Q3 FY28)
Commercial production start is the linchpin for FY28 margin accretion. Any delay (PPAP lag, customer approvals slip, construction snags) into Q4 FY28 pushes revenue/margin benefit out by 1–2 quarters. Watch for management updates on approval timelines and commissioning readiness.
3 · Order book and backlog visibility (Q3–Q4 guidance)
Management dodged quantifying order book on this call. Next quarter, expect analyst pushback for specific backlog months/years of coverage. Clarity here validates or invalidates the 'high mid-20s' aerospace growth guidance.
Raymond is a quality aerospace franchise executing well on the growth side—27% segment growth, capex discipline, new legs (aftermarket, defense). But operational leverage is proving elusive. Operating margin is stuck at 11.5% despite 24% revenue growth, a structural squeeze from freight and commodity inflation. The path to margin recovery is clear—Andhra facility (Dec 2027), cost normalization, customer price pass-through—but not guaranteed.
For holders: this is not a catalyst trade. It's a steady-execution story gated by Andhra capex, margin recovery (OPM back to 13–14%), and freight/commodity cost abatement. The single number to track from here is operating margin expansion and the timeline to Andhra commercial production. If Dec 2027 slips or costs remain sticky, the stock could re-test the 52-week lows (₹320). If both vectors hit (Andhra Dec on schedule, margin 13%+), upside to the ₹1,338.9 ATH is on the table. Until one of those resolves, the risk/reward is balanced. Hold and monitor Q3 capex/PPAP commentary and quarterly OPM trends.